​
​

Bausch Health Companies (BHC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BHC Stock Forecast

Bausch Health Companies stock forecast is as follows: an average price target of $10.00 (represents a 25.47% upside from BHC’s last price of $7.97) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.

BHC Price Target

The average price target for Bausch Health Companies (BHC) is $10.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $16.00 to $7.00. This represents a potential 25.47% upside from BHC's last price of $7.97.

BHC Analyst Ratings

Hold

According to 5 Wall Street analysts, Bausch Health Companies's rating consensus is 'Hold'. The analyst rating breakdown for BHC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (20.00%), 3 'Hold' (60.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

Bausch Health Companies Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2024Douglas MiehmRBC Capital--23.99%25.47%
Jul 25, 2024Les SulewskiTruist Financial--23.06%-12.17%
Jul 10, 2024Michael FreemanRaymond James--11.27%0.38%
Apr 29, 2024David AmsellemPiper Sandler--2.56%12.92%
Apr 23, 2024Doug MiehmRBC Capital--30.18%38.02%
Apr 11, 2024Glen SantangeloJefferies--72.51%100.75%
Apr 05, 2024Doug MiehmRBC Capital--19.40%50.56%
Sep 09, 2022Piper Sandler---10.45%-24.72%
Jul 26, 2022RBC Capital--37.38%50.56%
May 13, 2022RBC Capital--62.68%113.30%
Row per page
Go to

The latest Bausch Health Companies stock forecast, released on Oct 23, 2024 by Douglas Miehm from RBC Capital, set a price target of $10.00, which represents a 23.99% increase from the stock price at the time of the forecast ($8.06), and a 25.47% increase from BHC last price ($7.97).

Bausch Health Companies Price Target by Period

1M3M12M
# Anlaysts-17
Avg Price Target-$10.00$10.43
Last Closing Price$7.97$7.97$7.97
Upside/Downside-100.00%25.47%30.87%

In the current month, the average price target of Bausch Health Companies stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bausch Health Companies's last price of $7.97. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2024RBC CapitalSector PerformSector PerformHold
Aug 01, 2024Piper SandlerNeutralUnderweightDowngrade
Jul 10, 2024Raymond JamesMarket PerformInitialise
Apr 29, 2024Piper SandlerNeutralNeutralHold
Apr 08, 2024Cowen & Co.HoldHoldHold
Apr 05, 2024RBC CapitalSector PerformSector PerformHold
Mar 28, 2024JefferiesBuyBuyHold
Feb 23, 2024RBC CapitalSector PerformSector PerformHold
Sep 09, 2022Piper SandlerNeutralNeutralHold
Jul 26, 2022RBC CapitalOutperformOutperformHold
Row per page
Go to

Bausch Health Companies's last stock rating was published by RBC Capital on Oct 23, 2024. The company gave BHC a "Sector Perform" rating, the same as its previous rate.

Bausch Health Companies Financial Forecast

Bausch Health Companies Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$2.24B$2.17B$1.94B$2.19B$2.05B$1.97B$1.92B$2.20B$2.11B$2.10B$2.03B$2.21B$2.14B$1.66B$2.01B$2.22B$2.21B$2.15B$2.02B$2.00B$2.11B
Avg Forecast$2.63B$2.57B$2.48B$2.26B$2.51B$2.48B$2.35B$2.19B$2.33B$2.17B$2.03B$1.97B$2.14B$1.99B$2.04B$2.08B$2.19B$2.12B$2.11B$2.05B$2.17B$2.01B$1.78B$2.00B$2.23B$2.15B$2.18B$2.04B$1.36B$2.35B
High Forecast$2.67B$2.61B$2.52B$2.27B$2.57B$2.52B$2.39B$2.22B$2.36B$2.19B$2.07B$2.00B$2.17B$1.99B$2.04B$2.08B$2.19B$2.12B$2.11B$2.05B$2.17B$2.01B$1.78B$2.00B$2.23B$2.15B$2.18B$2.04B$1.63B$2.82B
Low Forecast$2.59B$2.54B$2.44B$2.25B$2.47B$2.44B$2.32B$2.16B$2.30B$2.15B$2.00B$1.94B$2.11B$1.99B$2.04B$2.08B$2.19B$2.12B$2.11B$2.05B$2.17B$2.01B$1.78B$2.00B$2.23B$2.15B$2.18B$2.04B$1.09B$1.88B
# Analysts11146311354433334444410101099992016
Surprise %---------1.03%1.07%0.99%1.03%1.03%0.96%0.92%1.00%1.00%0.99%0.99%1.02%1.06%0.94%1.01%1.00%1.03%0.99%0.99%1.47%0.90%

Bausch Health Companies's average Quarter revenue forecast for Dec 23 based on 3 analysts is $2.33B, with a low forecast of $2.30B, and a high forecast of $2.36B. BHC's average Quarter revenue forecast represents a 4.27% increase compared to the company's last Quarter revenue of $2.24B (Sep 23).

Bausch Health Companies EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11146311354433334444410101099992016
EBITDA---------$14.00M$412.00M$477.00M$710.00M$716.00M$636.00M$618.00M$724.00M$946.00M$96.00M$177.00M$412.00M$886.00M$427.00M$699.00M$-586.00M$859.00M$760.00M$812.00M$-1.49B$852.00M
Avg Forecast$745.46M$729.74M$703.25M$641.53M$712.45M$702.86M$666.54M$972.09M$662.65M$616.76M$576.92M$883.71M$682.63M$590.36M$605.23M$803.38M$648.59M$626.89M$625.73M$158.17M$643.27M$595.25M$526.16M$699.00M$660.92M$635.11M$644.67M$660.93M$-876.48M$940.14M
High Forecast$758.07M$742.09M$715.15M$644.37M$729.42M$714.76M$677.82M$1.17B$671.48M$621.06M$586.68M$1.06B$819.15M$590.36M$605.23M$964.05M$648.59M$626.89M$625.73M$189.80M$643.27M$595.25M$526.16M$838.80M$660.92M$635.11M$644.67M$793.12M$-701.18M$1.13B
Low Forecast$735.63M$720.12M$693.98M$638.69M$701.14M$693.60M$657.75M$777.67M$653.81M$611.17M$569.31M$706.97M$546.10M$590.36M$605.23M$642.70M$648.59M$626.89M$625.73M$126.54M$643.27M$595.25M$526.16M$559.20M$660.92M$635.11M$644.67M$528.74M$-1.05B$752.11M
Surprise %---------0.02%0.71%0.54%1.04%1.21%1.05%0.77%1.12%1.51%0.15%1.12%0.64%1.49%0.81%1.00%-0.89%1.35%1.18%1.23%1.70%0.91%

3 analysts predict BHC's average Quarter EBITDA for Dec 23 to be $662.65M, with a high of $671.48M and a low of $653.81M. This is 4633.20% upper than Bausch Health Companies's previous annual EBITDA (Sep 23) of $14.00M.

Bausch Health Companies Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11146311354433334444410101099992016
Net Income---------$-378.00M$131.00M$-209.00M$-410.00M$399.00M$-139.00M$-66.00M$72.00M$188.00M$-595.00M$-610.00M$-153.00M$71.00M$-326.00M$-152.00M$-1.52B$-49.00M$-171.00M$-52.00M$-2.69B$628.00M
Avg Forecast$461.50M$466.17M$391.35M$300.79M$412.29M$385.71M$323.98M$-106.64M$382.62M$341.34M$260.67M$-96.94M$65.06M$301.91M$337.27M$-88.13M$410.40M$380.75M$355.81M$-545.11M$418.09M$372.21M$243.13M$-152.00M$432.97M$400.41M$394.87M$-42.33M$-1.58B$692.97M
High Forecast$471.65M$476.42M$399.95M$328.77M$492.56M$386.00M$325.43M$-85.31M$394.10M$378.44M$266.40M$-77.55M$78.07M$301.91M$337.27M$-70.50M$410.40M$380.75M$365.08M$-436.09M$418.09M$372.21M$243.13M$-121.60M$432.97M$400.41M$394.87M$-33.86M$-1.26B$831.56M
Low Forecast$453.59M$458.18M$384.64M$279.81M$328.37M$385.42M$322.53M$-127.96M$378.80M$304.24M$256.20M$-116.33M$52.05M$301.91M$337.27M$-105.75M$410.40M$380.75M$346.54M$-654.13M$418.09M$372.21M$243.13M$-182.40M$432.97M$400.41M$394.87M$-50.79M$-1.90B$554.37M
Surprise %----------1.11%0.50%2.16%-6.30%1.32%-0.41%0.75%0.18%0.49%-1.67%1.12%-0.37%0.19%-1.34%1.00%-3.50%-0.12%-0.43%1.23%1.70%0.91%

Bausch Health Companies's average Quarter net income forecast for Sep 23 is $341.34M, with a range of $304.24M to $378.44M. BHC's average Quarter net income forecast represents a 160.56% increase compared to the company's last Quarter net income of $131.00M (Jun 23).

Bausch Health Companies SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11146311354433334444410101099992016
SG&A---------$715.00M$711.00M$725.00M$666.00M$661.00M$676.00M$622.00M$680.00M$653.00M$685.00M$606.00M$636.00M$572.00M$526.00M$633.00M$668.00M$648.00M$651.00M$587.00M$591.00M$661.00M
Avg Forecast$818.60M$801.34M$772.25M$704.48M$782.35M$771.83M$731.94M$961.27M$727.66M$677.28M$633.52M$873.88M$641.14M$621.78M$637.45M$794.44M$683.12M$660.26M$659.04M$541.53M$677.52M$626.93M$554.17M$633.00M$696.10M$668.92M$678.99M$477.79M$346.72M$729.38M
High Forecast$832.45M$814.89M$785.32M$707.59M$800.98M$784.88M$744.32M$1.15B$737.36M$681.99M$644.24M$1.05B$769.37M$621.78M$637.45M$953.32M$683.12M$660.26M$659.04M$649.84M$677.52M$626.93M$554.17M$759.60M$696.10M$668.92M$678.99M$573.35M$416.06M$875.26M
Low Forecast$807.81M$790.77M$762.07M$701.36M$769.93M$761.65M$722.29M$769.01M$717.96M$671.14M$625.17M$699.10M$512.91M$621.78M$637.45M$635.55M$683.12M$660.26M$659.04M$433.23M$677.52M$626.93M$554.17M$506.40M$696.10M$668.92M$678.99M$382.23M$277.38M$583.50M
Surprise %---------1.06%1.12%0.83%1.04%1.06%1.06%0.78%1.00%0.99%1.04%1.12%0.94%0.91%0.95%1.00%0.96%0.97%0.96%1.23%1.70%0.91%

Bausch Health Companies's average Quarter SG&A projection for Dec 23 is $727.66M, based on 3 Wall Street analysts, with a range of $717.96M to $737.36M. The forecast indicates a 1.77% rise compared to BHC last annual SG&A of $715.00M (Sep 23).

Bausch Health Companies EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11146311354433334444410101099992016
EPS---------$-1.03$0.36$-0.58$-1.13$1.10$-0.38$-0.18$0.20$0.52$-1.66$-1.71$-0.43$0.20$-0.92$-0.43$-4.30$-0.14$-0.49$-0.15$-7.68$1.80
Avg Forecast$1.25$1.27$1.06$0.82$1.12$1.05$0.88$0.69$1.04$0.93$0.71$0.65$0.94$0.82$0.91$1.05$1.11$1.03$0.96$0.95$1.13$1.01$0.66$0.86$1.17$1.08$1.07$0.86$0.35$0.96
High Forecast$1.28$1.29$1.09$0.89$1.34$1.05$0.88$0.69$1.07$1.03$0.72$0.66$0.96$0.82$0.91$1.05$1.11$1.03$0.99$0.95$1.13$1.01$0.66$0.86$1.17$1.08$1.07$0.86$0.42$1.15
Low Forecast$1.23$1.24$1.04$0.76$0.89$1.05$0.88$0.68$1.03$0.83$0.70$0.64$0.93$0.82$0.91$1.05$1.11$1.03$0.94$0.95$1.13$1.01$0.66$0.86$1.17$1.08$1.07$0.86$0.28$0.77
Surprise %----------1.11%0.51%-0.89%-1.20%1.35%-0.42%-0.17%0.18%0.51%-1.73%-1.81%-0.38%0.20%-1.40%-0.50%-3.68%-0.13%-0.46%-0.17%-21.94%1.88%

According to 5 Wall Street analysts, Bausch Health Companies's projected average Quarter EPS for Sep 23 is $0.93, with a low estimate of $0.83 and a high estimate of $1.03. This represents a 157.37% increase compared to BHC previous annual EPS of $0.36 (Jun 23).

Bausch Health Companies Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TLRYTilray Brands--453.73%Hold
EBSEmergent BioSolutions--443.25%Buy
ZTSZoetis--28.68%Buy
BHCBausch Health Companies--25.47%Hold
CTLTCatalent--21.76%Hold
NBIXNeurocrine Biosciences--17.27%Buy
TEVATeva Pharmaceutical Industries--16.82%Buy
VTRSViatris--2.84%Hold
PETQPetIQ--0.06%Buy
HLNHaleon---5.18%Buy
LFCRLifecore Biomedical---11.08%Buy

BHC Forecast FAQ

Is Bausch Health Companies a good buy?

No, according to 5 Wall Street analysts, Bausch Health Companies (BHC) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 20.00% of BHC's total ratings.

What is BHC's price target?

Bausch Health Companies (BHC) average price target is $10 with a range of $7 to $16, implying a 25.47% from its last price of $7.97. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Bausch Health Companies stock go up soon?

According to Wall Street analysts' prediction for BHC stock, the company can go up by 25.47% (from the last price of $7.97 to the average price target of $10), up by 100.75% based on the highest stock price target, and down by -12.17% based on the lowest stock price target.

Can Bausch Health Companies stock reach $12?

BHC's highest twelve months analyst stock price target of $16 supports the claim that Bausch Health Companies can reach $12 in the near future.

What are Bausch Health Companies's analysts' financial forecasts?

Bausch Health Companies's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $9.52B (high $9.7B, low $9.39B), average EBITDA is $3.05B (high $3.29B, low $2.83B), average net income is $1.02B (high $1.12B, low $908.36M), average SG&A $3.25B (high $3.48B, low $3.02B), and average EPS is $3.73 (high $3.96, low $3.5). BHC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.93B (high $10.07B, low $9.82B), average EBITDA is $2.82B (high $2.86B, low $2.79B), average net income is $1.62B (high $1.68B, low $1.58B), average SG&A $3.1B (high $3.14B, low $3.06B), and average EPS is $4.4 (high $4.55, low $4.28).

Did the BHC's actual financial results beat the analysts' financial forecasts?

Based on Bausch Health Companies's last annual report (Dec 2022), the company's revenue was $8.12B, which missed the average analysts forecast of $8.25B by -1.58%. Apple's EBITDA was $2.58B, missing the average prediction of $2.68B by -3.60%. The company's net income was $-212M, missing the average estimation of $616.1M by -134.41%. Apple's SG&A was $2.62B, missing the average forecast of $2.69B by -2.59%. Lastly, the company's EPS was $-0.59, missing the average prediction of $3.72 by -115.86%. In terms of the last quarterly report (Sep 2023), Bausch Health Companies's revenue was $2.24B, beating the average analysts' forecast of $2.17B by 3.04%. The company's EBITDA was $14M, missing the average prediction of $616.76M by -97.73%. Bausch Health Companies's net income was $-378M, missing the average estimation of $341.34M by -210.74%. The company's SG&A was $715M, beating the average forecast of $677.28M by 5.57%. Lastly, the company's EPS was $-1.03, missing the average prediction of $0.927 by -211.17%